Sumitomo Pharma Switzerland
Basel-based Swiss pharmaceutical subsidiary of Sumitomo Pharma Co., Ltd., formed in 2023 by consolidating four Swiss entities to develop and commercialize therapies across oncology, urology, women's health, rare disease, cell and gene therapies, and CNS disorders.
- Company typePrivate
- Founded2023
- HeadquartersBasel, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Sumitomo Pharma Switzerland does
Sumitomo Pharma Switzerland GmbH is a Basel-based, wholly-owned Swiss subsidiary of Japan's Sumitomo Pharma Co., Ltd., established in 2023 through the consolidation of four pre-existing Swiss entities within the Sumitomo Pharma Group: Enzyvant Therapeutics GmbH (rare disease), Altavant Sciences GmbH (rare disease/specialty therapeutics), Urovant Sciences GmbH (urology), and Myovant Sciences GmbH (women's health and oncology). The entity operates as the European specialty-pharma operating company for the Sumitomo Pharma Group, headquartered at Aeschengraben 27, Basel, and licensed to use the Sumitomo and Sumitomo Pharma trademarks of Sumitomo Chemical Co., Ltd. and Sumitomo Pharma Co., Ltd. respectively.
The company's product portfolio is organized around six therapeutic areas: oncology, urology, women's health, rare disease, cell & gene therapies, and CNS disorders. The portfolio is described at the therapeutic-area and legacy-brand level rather than as discrete named drug products, indicating that commercial activity is driven by established specialty franchises inherited from the four predecessor entities, augmented by cell & gene therapy programs not previously housed in a single Swiss vehicle. The technical core is therefore conventional small-molecule and biologic specialty pharma plus advanced cell & gene therapy modalities, with no disclosed proprietary software or computational platform.
The business model is that of a wholly-owned operating subsidiary: revenue is generated through the prescription pharmaceutical supply chain (pharmacies, hospitals, and healthcare providers) but is ultimately consolidated into the parent, Sumitomo Pharma Co., Ltd. (established 1897, itself part of the Sumitomo Group with approximately 400 years of history). No pricing, revenue, or headcount data is publicly disclosed. The Swiss entity's stated mission is to "accelerate scientific and therapeutic breakthroughs on behalf of patients in critical disease areas," reflecting parent-company direction rather than independent commercial positioning.
Sumitomo Pharma Switzerland firmographics
Firmographics- Name
- Sumitomo Pharma Switzerland
- Legal name
- Sumitomo Pharma Switzerland GmbH
- Website
- https://myovant.ch
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Basel-based Swiss pharmaceutical subsidiary of Sumitomo Pharma Co., Ltd., formed in 2023 by consolidating four Swiss entities to develop and commercialize therapies across oncology, urology, women's health, rare disease, cell and gene therapies, and CNS disorders.
- Ownership category
- akta.pro rank
Sumitomo Pharma Switzerland industry classification
Industry- Product category
- Pharmaceutical Products
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where Sumitomo Pharma Switzerland is headquartered
LocationHeadquarters
- HQ city
- Basel
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Sumitomo Pharma Switzerland business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Sumitomo Pharma Switzerland product offering
Product offeringCore offering
Sumitomo Pharma Switzerland GmbH is a Swiss pharmaceutical company that develops and manages prescription therapies across oncology, urology, women's health, rare diseases, cell & gene therapies, and CNS disorders. The company was formed through consolidation of four Swiss entities of the Sumitomo Pharma Group (Enzyvant Therapeutics GmbH, Altavant Sciences GmbH, Urovant Sciences GmbH, and Myovant Sciences GmbH) and operates as a wholly-owned subsidiary of Sumitomo Pharma Co., Ltd. (Japan, established 1897).
Product overview
Sumitomo Pharma Switzerland GmbH is a pharmaceutical company formed through the consolidation of four Swiss entities: Enzyvant Therapeutics GmbH, Altavant Sciences GmbH, Urovant Sciences GmbH, and Myovant Sciences GmbH. The company operates as a unified platform offering treatments across six key therapeutic areas: oncology, urology, women's health, rare disease, cell & gene therapies, and CNS. The acquired brands represent specialized focuses in rare disease (Enzyvant, Altavant), urology (Urovant), and women's health/oncology (Myovant), while the broader therapeutic portfolios provide cross-brand coverage in core disease areas. The company is a subsidiary of Sumitomo Pharma Co., Ltd., established in 1897.
Differentiator
Problem solved
Functional benefit
Products and services
- Oncology Portfolio Pharmaceutical treatments focused on cancer therapy and oncology care, serving patients with oncological conditions.
- Urology Portfolio Pharmaceutical treatments for urological conditions and diseases, addressing unmet needs in urological care.
- Women's Health Portfolio Pharmaceutical treatments addressing women's health conditions.
- Rare Disease Portfolio Pharmaceutical treatments for rare and orphan diseases, addressing critical unmet medical needs.
- Cell & Gene Therapies Advanced cell and gene therapy treatments for patients with serious medical conditions.
- CNS (Central Nervous System) Portfolio Pharmaceutical treatments for central nervous system disorders and diseases.
Companies that use Sumitomo Pharma Switzerland
Customer profileSegments1 record
Ideal customer profiles1 record
Sumitomo Pharma Switzerland technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Sumitomo Pharma Switzerland partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Sumitomo Pharma Co., Ltd.coreParent company established in 1897, part of Sumitomo Group with approximately 400 years of history. Sumitomo Pharma Switzerland GmbH is a subsidiary of Sumitomo Pharma Co., Ltd.
Scale indicators1 record
Recent moves5 records
Expansion highlights4 records
Sumitomo Pharma Switzerland competitors and assessment
Company assessmentDirect peers
- Novartis: Basel-headquartered Swiss pharma giant operating across innovative specialty medicines including oncology, rare disease, and CNS. Direct comparable on geography and specialty pharma mandate.
- UCB: Belgian specialty pharma with franchises in CNS, neurology, and rare diseases. Comparable positioning to Sumitomo Pharma Switzerland's Enzyvant/Altavant-derived rare-disease and CNS platforms.
- Roche: Basel-based global pharmaceutical major with a specialty/innovative pharma focus that overlaps Sumitomo Pharma Switzerland in oncology, rare disease, and women's health therapy areas. Same geography, similar therapeutic scope, comparable European commercialization footprint.
- Ferring Pharmaceuticals: Swiss specialty pharma company headquartered near Lausanne with emphasis on women's health, urology, and reproductive medicine. Closely comparable to Sumitomo Pharma Switzerland's urology and women's health franchises from Myovant and Urovant.
- Ipsen: France-headquartered specialty pharma focused on oncology, urology, and rare diseases with a strong European footprint. Directly comparable across three of Sumitomo Pharma Switzerland's therapeutic areas.
- Recordati: Italian specialty pharma with franchises in urology, women's health, and rare diseases. Compares directly to Sumitomo Pharma Switzerland's Urovant-derived urology and specialty rare-disease portfolios.
- Astellas Pharma: Japanese specialty pharmaceutical major with strong urology (Vesicare) and oncology franchises. Strongly comparable to Sumitomo Pharma Switzerland's urology and oncology therapeutic pillars.
- Otsuka Pharmaceutical: Japanese specialty pharma notable for CNS and women's health assets plus rare disease activity. Comparable to Sumitomo Pharma Switzerland's CNS portfolio and women's health franchise.
- Lundbeck: Danish specialty pharma squarely focused on CNS disorders; comparable in CNS and rare disease categories overlapping Sumitomo Pharma Switzerland's therapeutic scope.
Broad incumbents
- Takeda Pharmaceutical: Japanese-headquartered global pharma with significant specialty and rare-disease exposure post-Shire acquisition. Provides a comparable Japanese-parent specialty pharma template and competes in oncology and rare disease areas.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights5 records
Customer concentration
Sumitomo Pharma Switzerland social profiles
Digital presenceSumitomo Pharma Switzerland financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sumitomo Pharma Switzerland leadership team
Management profileNumber of profiles
Sumitomo Pharma Switzerland funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sumitomo Pharma Switzerland M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sumitomo Pharma Switzerland
What does Sumitomo Pharma Switzerland do?
Sumitomo Pharma Switzerland GmbH is a Swiss pharmaceutical company that develops and manages prescription therapies across oncology, urology, women's health, rare diseases, cell & gene therapies, and CNS disorders. The company was formed through consolidation of four Swiss entities of the Sumitomo Pharma Group (Enzyvant Therapeutics GmbH, Altavant Sciences GmbH, Urovant Sciences GmbH, and Myovant Sciences GmbH) and operates as a wholly-owned subsidiary of Sumitomo Pharma Co., Ltd. (Japan, established 1897).
Is Sumitomo Pharma Switzerland a public or private company?
Sumitomo Pharma Switzerland is a private company. It is classified as corporate owned and is currently operating.
When was Sumitomo Pharma Switzerland founded?
Sumitomo Pharma Switzerland was founded in 2023. It employs 1 to 10 people.
Where is Sumitomo Pharma Switzerland based?
Sumitomo Pharma Switzerland is headquartered in Basel, Switzerland, in the Europe region.
Who are Sumitomo Pharma Switzerland's main competitors?
Direct peers on record are Novartis, UCB, Roche, Ferring Pharmaceuticals, Ipsen, Recordati, Astellas Pharma, Otsuka Pharmaceutical and Lundbeck. Takeda Pharmaceutical is listed as a broad incumbent.
Does Sumitomo Pharma Switzerland have an API?
No public API is recorded for Sumitomo Pharma Switzerland.
What industry is Sumitomo Pharma Switzerland in?
Sumitomo Pharma Switzerland's product category is Pharmaceutical Products. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.